Growth hormone deficiency (GHD) is the most commonly affected pituitary hormone in childhood with a prevalence of 1 in 4000–10000 live births. GH stimulation testing (GHST) is commonly used in the diagnostic workup of GHD. However, GHD can be diagnosed in some clinical conditions without the need of GHST. The diagnosis of GHD in newborns does not require stimulation testing. Likewise infants/children with delayed growth and/or short stature associated with neuroradiological abnormalities and one or more additional pituitary hormone deficiencies may not need GHST. This review summarizes the current evidence on the diagnosis of GHD without stimulation tests.

Keywords: children, growth, growth hormone, IGF-1, growth hormone stimulation tests, newborn

INTRODUCTION

Growth hormone deficiency (GHD) has a prevalence of 1:4000-10000, most cases are isolated (IGHD) and the majority of them are idiopathic. GHD can also be combined with other pituitary hormone deficiencies (multiple pituitary hormone deficiency-MPHD). Both IGHD and MPHD can be congenital or acquired (tumours, trauma, brain infections, radiotherapy). Congenital IGHD can be due to genetic mutations in the genes encoding GH (GH1) or the GH-releasing hormone receptor (GHRHR) (1, 2). Mutations in the genes encoding transcription factors like SOX3, HESX1, GLI2, OTX2, LHX3, LHX4, PROP1, and POU1F1 usually cause MPHD (3) but, occasionally, GHD can be the only pituitary hormone deficiency (1, 2). GHD can develop at any age, so the signs and symptoms vary accordingly. GHD in newborns may present with hypoglycaemia, jaundice, or with underdeveloped male genitalia, whereas in older children it manifests primarily with short stature and/or decreased growth (4).

In the last decades the diagnosis of idiopathic IGHD has been the subject of intensive debate and it is still controversial. GH stimulation testing is not necessary in neonates and also in infants with a combination of clinical signs of GHD, low insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3), MPHD and/or an abnormal brain magnetic resonance imaging (MRI) (5, 6).

The most recent guidelines (7) still recommend to perform GHSTs in children and adolescents with suspected GHD. However, some authors (8, 9) suggest that also in this age group the diagnosis of GHD may be based on a combination of auxological, biochemical (IGF-1 and IGFBP-3), neuroradiological and genetic findings and that GHSTs are not always necessary. It should be pointed out that the diagnosis of GHD is primarily auxologic (10, 11).
In this review we summarize the current evidence on the diagnosis of GHD without the use of GHSTs in the paediatric population.

**PHYSIOPATHOLOGY**

GH is a 191-amino acid protein synthesized, stored and secreted in a pulsatile manner by pituitary somatotroph cells. The synthesis and release of GH are under the control of various hormones, including GH-releasing hormone (GHRH), somatostatin, ghrelin, IGF-1, thyroid hormone, gonadal steroids and glucocorticoids. At birth and in the first week of life, GH levels are high and pulsatile, with elevated baseline, mean and peak levels (4) and rapidly decrease during the following weeks and increase with chronic malnutrition, chronic kidney disease, exercise, trauma and sepsis (12). GH plays a key role in glucose and fat metabolism in the newborn (4, 13), in increasing bone length and density in children and adolescents, but also in increasing muscle mass, regulating lipid and carbohydrates metabolism and body water throughout life. GH action is exerted directly on target tissues or indirectly by insulin growth factors (IGFs) (14). IGF-1, the main GH effector, is mostly secreted by the liver, and circulates bound to specific insulin growth factor binding protein (IGFBPs 1-6), mainly IGFBP-3. IGF-1 secretion is influenced also by malnutrition, thyroid hormone, sex hormones, chronic diseases and inflammation and anorexia nervosa (15–19). In contrast, IGF-1 values remain low for at least the first 15–18 months of age and increase until a pubertal peak (20, 21). Measurement of a random serum GH level is not helpful for the diagnosis of GHD except in some specific cases (see below). In fact, serum GH levels between normal pulses of GH secretion are often low, below the limits of sensitivity of most conventional assays. For these reasons stimulation tests have been introduced into the diagnostic workup of GHD many years ago. A large number of GHSTs have been proposed in the last decades (6, 22–25). However, GHSTs are not physiological, have poor specificity and reproducibility (24), and cause a high number of false pathological responses. Furthermore, there are no age- and gender-related normative data, and the diagnostic cut-offs are often arbitrarily established. In addition, GH secretion is influenced by several factors (such obesity, undernutrition, puberty) and entails high costs and discomfort for the patients. Notwithstanding the above limitations, GHSTs are still used as the gold standard for the diagnosis of paediatric GHD (7, 26–29). These limitations are even more evident in children younger than 4 years, in which the accuracy of stimulation tests has not been formally addressed, and most of the currently used tests are burdened by side effects (5, 24). For all the above reasons the decision to perform a GHST should be well reasoned and based on the severity of short stature, height velocity, medical history and physical examination findings. The diagnostic GH peak cut-off is still matter of discussion between scientific societies, and so far it has been arbitrarily established by the single centre and currently ranges between 3 to 10 μg/L (6, 7, 11, 22, 24, 27, 30–32).

**CLINICAL PRESENTATION OF GHD**

**Newborn**

In consideration of the important metabolic role of GH in the neonatal period, the prompt identification of a newborn with GHD is crucial to start replacement treatment rapidly. GHD in neonates can be isolated but often presents as MPHDS, and the clinical presentation and its severity depend on the number of affected hormones. Neonates might present non-specific symptoms and signs, such as lethargy and poor weight gain, or more specific life-threatening emergencies (33), including respiratory distress, apnoea, cyanosis, poor feeding, hypotonia, long-term cholestatic jaundice, severe hypoglycaemia with or without seizures, temperature dysregulation, electrolyte abnormalities, haemodynamic instability and/or neonatal sepsis. Other physical findings can suggest the presence of GHD such as eye abnormalities, microphallus, microphthalmia and single central maxillary incisor. Intrauterine growth is generally not affected by GHD, and birth weight and length are usually within normal limits, although slightly reduced.

**Infant/Child**

Short stature, defined as a height more than 2 SD below the population mean, or growth arrest/deceleration with normal/ increased weight and delayed skeletal maturation may be the only signs of GHD in infancy and childhood. Diminished height velocity often precedes short stature. The typical GHD clinical phenotype in infants is persistent growth failure and/or short stature associated with truncal adiposity and micropenis, immature appearance, mid-facial hypoplasia, delayed dentition and frontal bossing with depressed nasal bridge.

Most cases of IGHD in childhood are idiopathic. However, pituitary masses, brain tumours, infections of central nervous system should always be ruled out. Furthermore, GHD should be suspected in short children who underwent cranial irradiation (34, 35) or suffered from brain injuries (36).

**ESTABLISHING A DIAGNOSIS**

**Newborn**

The neonatal period is characterized by high GH levels (hypersomatotropism of the newborn) (37, 38), which enable the diagnosis of GHD without the use of pharmacological stimulation (20, 39). Furthermore GHSTs are contraindicated under the age of 1-2 years (2). Reasons for this are primarily due to safety (GHSTs need a fasting period), to the amount of time needed, to the potential for hypoglycaemia, or other side effects depending on the GH secretagogue used.

A single low GH measurement is traditionally used to confirm the clinical suspicion of neonatal GHD. The sample is preferably taken during hypoglycaemic episodes (critical sample), in plasma, serum or newborn screening cards (39) within the first week of life. However, the specificity of a single GH measurement during spontaneous hypoglycaemia has been questioned, and some authors (40) do not deem it sufficient to diagnose GHD.
However, the observation of normal GH concentration can be useful to exclude GHD. Over the years, various cut-offs of GH as indicative of GH sufficiency in the newborn have been proposed ranging from 7 to 20 µg/L during an hypoglycaemic episode (20, 22). Recently, Binder et al. (39) demonstrated that GH concentration <7 µg/L in the newborn screening card confirms severe GHD with high accuracy in term newborns with a specific phenotype such as recurrent hypoglycaemia, additional pituitary hormone deficiencies and/or a significant hypothalamic-pituitary abnormality on cerebral MRI (Table 1). The use of newborn screening card still needs to be validated since its reliability has not been confirmed (41). According to current guidelines (7) the diagnosis of GHD in newborns is possible in the presence of GH concentrations ≤5 ng/mL in a newborn with additional pituitary hormone deficiencies or/and the triad of ectopic posterior pituitary, pituitary hypoplasia and abnormal pituitary stalk (Table 1).

**Infant/Child**

An accurate and early diagnosis is important for a prompt treatment initiation, essential to optimize child growth and adult height and to avoid co-morbidities such as impaired quality of life, bone and metabolic health (7, 26). Despite more than 50 years of paediatric hGH replacement, the ability to make a definitive diagnosis of GHD in children is still limited. The diagnosis of GHD is traditionally based on auxology and the lack of response to two different GHSTs, but it is not always straightforward (10).

In infants with history of hypoglycaemia, hyperbilirubinemia, poor growth, midline defects, microphallus, low IGF-1 and IGFBP-3, multiple pituitary hormone deficiencies (congenital or acquired), and one additional pituitary hormone deficiency (Table 1). However, according to some authors (26) there are more conditions in which GHSTs might be not necessary, such as in case of acquired GHD due to intracranial tumours, severe traumatic brain injury or cranial radiotherapy (Table 2). Given to the lack of sufficient evidence, the guidelines do not recommend establishing the diagnosis of GHD without GHSTs in patients with these conditions (7, 34, 35). Due to the low reliability of the GHSTs, alternative diagnostic strategies such as measurement of IGF-1 and IGFBP-3, genetic testing and neuroimaging have been considered over the years for the diagnosis of GHD in children (5, 8, 9, 42). In our opinion, patients with auxological characteristics associated with abnormal hypothalamic/pituitary morphology and low IGF-1 do not require GHST.

Recently Clément et al. (26) developed and validated an accurate clinical prediction rule for the diagnosis of GHD without GHSTs in children who meet the criteria required for GHSTs according to the guidelines (22), but with specific comorbidities such as the presence of pituitary dysgenesis on MRI or two or more anterior pituitary hormone deficiencies (Table 2).

However, recent guidelines (6) still consider the measurements of IGF-1, IGFBP-3 levels, brain MRI and genetic tests only as a support for the diagnosis.

**IGF-1 and IGFBP-3**

Measurement of IGF-1 is considered not useful in newborns since its levels remain low for at least the first 15–18 months of age and then progressively increase reaching a peak at mid-puberty (20, 21). The usefulness of IGF-1 measurement in children, alone or in combination with IGFBP-3, for the diagnosis of GHD has been the subject of a number of studies (7, 18, 23, 28, 30, 31, 42–50). The results of all these studies have been controversial, and their findings are hardly comparable because of the use of different assays, different measure unit (µg/ml, percentiles, SDS), as well as patients’ selection (43). However, most studies showed poor sensitivity and specificity in the diagnosis of GHD in children and most authors concluded that IGF-1 measurement is useful for the diagnosis of GHD only when combined with auxological parameters and the results of GHSTs (31, 42, 44, 46, 51–53). IGF-1 levels should be interpreted taking into consideration age, gender, pubertal status and body mass index (18). Moreover reduced IGF-1 levels may be observed children with malnutrition (19), hypothyroidism, hepatic disease or diabetes mellitus and there is overlap between normal and GHD children. Therefore, although very low levels of IGF-1 are strongly suggestive of GHD, normal IGF-1 concentrations do not exclude GHD at any age (54). Wit et al. (18) recently proposed specific steps for the clinicians for the use of IGF-1 measurement to estimate the probability of GHD in a child with growth failure based on pre- and post-test likelihood. In our personal experience about 40% of patients with severe GHD have IGF-1 concentrations higher than -2 SDS, overlapping values found in non-GHD children (53).

IGFBP-3 levels have also been considered for the diagnosis of GHD since it is less influenced by nutrition than IGF-1.

---

**TABLE 1** Conditions in which it is not necessary to perform GHSTs according to current guidelines (6, 7, 22, 39).

| Newborns                                                                 |
|------------------------------------------------------------------------|
| GH ≤ 7 µg/L during hypoglycaemia episode with a specific phenotype      |
| Random GH ≤ 5 ng/mL with additional pituitary hormone deficiencies or/and the triad of ectopic posterior pituitary, pituitary hypoplasia and abnormal stalk |
| Infants                                                                 |
| Suggestive history of clinical GHD (short stature and/or low height velocity), low IGF-1 and IGFBP-3, multiple pituitary hormone deficiencies, and/or an abnormal cranial MRI |
| Children                                                               |
| Auxological characteristics (short stature and/or low height velocity), presence of hypothalamic-pituitary defects (congenital or acquired), and one additional pituitary hormone deficiency |

---
TABLE 2 | Conditions in which it is not necessary to perform GHSTs. Modified from Clément et al. (26).

| Auxological criteria required for performing GHSTs according to the Summary Statement of the Growth Hormone Research Society (22): |
|---|
| 1) severe short stature, defined as a height more than 3 SD below the mean; 2) height more than 1.5 SD below the midparental height; 3) height more than 2 SD below the mean and a height velocity over 1 year more than 1 SD below the mean for chronological age, or a decrease in height SD of more than 0.5 over 1 year in children over 2 year of age; 4) in the absence of short stature, a height velocity more than 2 SD below the mean over 1 year or more than 1.5 SD sustained over 2 year; 5) signs indicative of an intracranial lesion; 6) signs of MPHD; 7) neonatal symptoms and signs of GHD. |

PLUS
- Pituitary dysgenesis on MRI
- Two or more anterior pituitary hormone deficiencies
- At least one anterior pituitary hormone deficiency plus one of the following:
  - a. Neonatal symptoms of pituitary deficiency (hypoglycaemia or hypogenitalism)
  - b. Central diabetes insipidus
  - c. Clinical or radiological craniofacial midline abnormalities
  - d. Suprasellar or sellar tumor/surgery
  - e. Cranial radiotherapy ≥18 Gy

However, many studies have reported no advantage of measuring IGFBP-3 over IGF-1 (55).

Magnetic Resonance Imaging
The differential diagnosis of hypopituitarism has greatly improved thanks to diagnostic accuracy of MRI that has increased our knowledge of pituitary morphology and function (56, 57). Brain MRI with a focus on the pituitary and hypothalamus is essential during the initial evaluation of newborns with midline defects, microphallus, and hypoglycaemia. In a infant with a highly suspicious history of GHD, plus other pituitary hormone deficiencies, or neurologic abnormalities, the presence of an abnormal brain MRI allows the diagnosis of GHD without GHSTs (6). Abnormalities found on MRI that are more suggestive of GHD include the absence of the anterior pituitary gland (empty sella), an ectopic posterior pituitary gland, and hypoplasia/absence of the pituitary stalk and/or pituitary gland (58). However the presence of a small pituitary gland by itself is not sufficient to make the diagnosis of GHD, but it may suggest the need for a more extensive evaluation of pituitary function (6). In children younger than 4 years, MRI has been proposed as first-line investigation (5) in order to reduce cost/benefit ratio and allow earlier start of treatment, and to postpone GHSTs to an age when they can be more easily performed and interpreted. Neuroimaging in association with IGF-1 assessment has been proposed about 20 years ago in children with clinical suspicion of GHD as an alternative to GHSTs (8). However the current guidelines (6) still recommend to perform MRI of the hypothalamus and pituitary after the diagnosis of GHD is confirmed by GHSTs. Therefore, if GHD has been excluded by GHSTs, MRI is typically not indicated. Early onset of growth failure, positive family history, height more than 3 SD below the mean, extremely low GH response to GHSTs and, very low IGF-1 and IGFBP-3 levels. The most common mutations in patients with isolated GHD have been identified in GH1 and GHRHR genes and may be associated with a normal MRI scan. Other gene mutations (i.e. POU1F1, PROP1, LHX3, LHX4, HESX1, SOX2, SOX3, etc.) are generally associated with MPHD (2), and present with typical clinical and neuroradiological features. With a greatly use of genetic testing it is possible that other conditions may include GHD in the differential diagnosis (59).

CONCLUSIONS
In most cases of suspected GHD current guidelines still recommend the use of GHSTs plus auxological criteria. However, GHSTs are not accurate, and in some instances a diagnosis can be made based on other clinical, laboratory, genetic and neuroimaging evaluation. IGF-1 and IGFBP-3 measurement have high specificity but low sensitivity and thus normal concentrations do not exclude GHD at any age. MRI of the hypothalamic–pituitary region might be helpful in identifying GHD when associated with other cerebral abnormalities, and genetic testing can provide definitive diagnosis in some selected patients. The diagnosis of GHD may be straightforward in neonates, infants and children with organic lesions, irradiation or trauma, but is still puzzling in all other conditions, requiring careful clinical, laboratory and imaging investigation.

AUTHOR CONTRIBUTIONS
Both authors contributed equally to the design and writing of the review. All authors contributed to the article and approved the submitted version.
35. Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Collin F, Meacham LR, et al. Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society® Clinical Practice Guideline. J Clin Endocrinol Metab (2018) 103:2761–84. doi: 10.1210/jc.2018-01175

36. Dassa Y, Crosnier H, Chevignard M, Vialad M, Personnere C, Flecheter I, et al. Pituitary Deficiency and Precocious Puberty After Childhood Severe Traumatic Brain Injury: A Long-Term Follow-Up Prospective Study. Eur J Endocrinol (2019) 180:281–90. doi: 10.1530/EJE-19-00334

37. Laron Z, Mannheimer S, Pertzelan A, Nitzan M. Serum Growth Hormone Concentration in Full Term Infants. Isr J Med Sci (1966) 2:770–3.

38. Cornblath M, Parker ML, Reisner SH, Forbes AE, Daughaday WH. Secretion and Metabolism of Growth Hormone in Premature and Full-Term Infants. J Clin Endocrinol Metab (1965) 25:209–18. doi: 10.1210/jcem-25-2-209

39. Binder G, Weber K, Rieflin N, Steinruck L, Blumenstock G, Janzen N, et al. Diagnosis of Severe Growth Hormone Deficiency in the Newborn. Clin Endocrinol (2020) 93(3):305–11. doi: 10.1111/cen.14264

40. Kelly A, Tang R, Becker S, Stanley CA. Poor Specificity of Low Growth Hormone and Cortisol Levels During Fasting Hypoglycemia for the Diagnoses of Growth Hormone Deficiency and Adrenal Insufficiency. PEDiATRICS (2008) 122:e522–8. doi: 10.1542/peds.2008-0806

41. Dominguez-Menéndez G, Cifuentes L, González C, Lagos M, Quiroga T, Rumí H, et al. Hormona De Crecimiento En Sangre De Papel Filtro Para El Diagnóstico De Deficiencia De Hormona De Crecimiento. Rev Chil Pediatr (2019) 90:145. doi: 10.32641/rcped.v90i2.674

42. Cianfarani S, Tondinelli T, Spadoni GL, Scire G, Boemi S, Boscherini B. Height Velocity and IGF-1 Assessment in the Diagnosis of Childhood Onset GH Insufficiency: Do We Still Need a Second GH Stimulation Test? Clin Endocrinol (2002) 57:161–7. doi: 10.1111/j.1365-2265.2002.01591.x

43. Shen Y, Zhang J, Zhao Y, Yan Y, Liu Y, Cai J. Diagnostic Value of Serum IGF-1 and IGFBP-3 in Growth Hormone Deficiency: A Systematic Review With Meta-Analysis. Eur J Pediatr (2015) 174:419–27. doi: 10.1007/s00431-014-2046-3

44. Study Group on Pathophysiology of growth processes and Council of ISPED, Federico G, Street ME, Maghnie M, Caruso-Nicoletti M, et al. Assessment of Serum IGF-1 Concentrations in the Diagnosis of Isolated Childhood-Onset GH Deficiency: A Proposal of the Italian Society for Pediatric Endocrinology and Diabetes (SIEDP/ISPED). J Endocrinological Invest (2006) 29:732–7. doi: 10.1007/BF03344184

45. Wang Y, Zhang H, Cao M, Kong L, Ge X. Analysis of the Value and Correlation of IGF–1 With GH and IGFBP–3 in the Diagnosis of Dwarfism. Exp Ther Med (2019) 17(5):3689–93. doi: 10.3892/etm.2019.7393

46. Boquete HR, Sobrado PGV, Fideleff HL, Sequera AM, Giaccio AV, Suaez MG, et al. Evaluation of Diagnostic Accuracy of Insulin-Like Growth Factor (IGF)-1 and IGF-Binding Protein-3 in Growth Hormone-Deficient Children and Adults Using ROC Plot Analysis. J Clin Endocrinol Metab (2003) 88:4702–8. doi: 10.1210/jc.2003-030412

47. Bussières L, Souberbielle J-C, Pinto G, Adan L, Maek ́ca E, Zender E. Usefulness of Magnetic Resonance Findings of the Hypothalamic-Pituitary Region in the Management of Short Children With Growth Hormone Deficiency: Evidence From a Longitudinal Study. Childs Nerv Syst (2012) 28:121–7. doi: 10.1007/s00381-011-1594-7

48. Shin Y, Zhang J, Zhao Y, Yan Y, Liu Y, Cai J. Diagnostic Value of Serum IGF-1 and IGFBP-3 in Growth Hormone Deficiency: A Systematic Review With Meta-Analysis. Eur J Pediatr (2015) 174:419–27. doi: 10.1007/s00431-014-2046-3

49. Study Group on Pathophysiology of growth processes and Council of ISPED, Federico G, Street ME, Maghnie M, Caruso-Nicoletti M, et al. Assessment of Serum IGF-1 Concentrations in the Diagnosis of Isolated Childhood-Onset GH Deficiency: A Proposal of the Italian Society for Pediatric Endocrinology and Diabetes (SIEDP/ISPED). J Endocrinological Invest (2006) 29:732–7. doi: 10.1007/BF03344184

50. Inoue-Lima TH, Vasques GA, Scalco RC, Nakaguma M, Mendonca BB, Arnhold JP, et al. IGF-1 Assessed by Pubertal Status has the Best Possible Predictive Power for GH Deficiency Diagnosis in Peripubertal Children. J Pediatr Endocrinol Metab (2019) 32:173–9. doi: 10.1515/jpem-2018-0435

51. Federico G, Cianfarani S. Usefulness of Serum Insulin-Like Growth Factor I Assessment in the Diagnosis of Childhood-Onset Growth Hormone Deficiency. Hormone Res Paediatrics (2010) 74:145–8. doi: 10.1159/000314895

52. Alawneh H, Khaledi O, Maia J. Insulin Like Growth Factor 1 as an Indicator of Growth Hormone Deficiency. JRMS (2015) 22:13–7. doi: 10.12816/0011355

53. Ibba A, Corrias F, Guzzetti C, Casula L, Salerno M, di Iorgi N, et al. IGFl for the Diagnosis of Growth Hormone Deficiency in Children and Adolescents: A Reappraisal. Endocrine Connections (2020) 9:1095–102. doi: 10.1530/EC-20-0347

54. Cianfarani S, Liguori A, Boemi S, Maghnie M, Iuggetti L, Wasiennska M, et al. Inaccuracy of Insulin-Like Growth Factor (IGF) Binding Protein (IGFBP)-3 Assessment in the Diagnosis of Growth Hormone (GH) Deficiency From Childhood to Young Adulthood: Association to Low GH Dependency of IGF-II and Presence of Circulating IGFBP-3. 18-Kidalotadon Fragment. J Clin Endocrinol Metab (2005) 90:6028–34. doi: 10.1210/jc.2005-0721

55. Phillip M, Chalew SA, Kowarski AA, Stene MA. Plasma IGFBP-3 and Its Relationship With Quantitative Growth Hormone Secretion in Short Children. Clin Endocrinol (1993) 39:427–32. doi: 10.1111/j.1365-2265.1993.tb02389.x

56. Hage C, Gan H-W, Ibba A, Patti G, Dattani M, Loche S, et al. Advances in Differential Diagnosis and Management of Growth Hormone Deficiency in Children. Nat Rev Endocrinol (2021) 17:608–24. doi: 10.1038/s41574-021-00539-5

57. Iorgi ND, Allegri AEM, Napoli F, Bertelli E, Olivieri I, Rossi A, et al. The Use of Neuroimaging for Assessing Disorders of Pituitary Development: Assessing Disorders of Pituitary Development. Clin Endocrinol (2012) 76:161–76. doi: 10.1111/j.1365-2265.2011.04238.x

58. Kalina MA, Kalina-Faska B, Gruszczynski K, Baron J, Malecka-Tendera E. Usefulness of Magnetic Resonance Findings of the Hypothalamic-Pituitary Region in the Management of Short Children With Growth Hormone Deficiency: Evidence From a Longitudinal Study. Childs Nerv Syst (2012) 28:121–7. doi: 10.1007/s00381-011-1594-7

59. Wit JM, Oostdijk W, Losekoort M, van Duyvenvoorde HA, Ruijvenkamp CAL, Kant SG. Mechanisms in Endocrinology: Novel Genetic Causes of Short Stature. Eur J Endocrinol (2016) 174:R145–73. doi: 10.1530/EJE-15-0937

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.